Drug intelligence / Profile preview

GD-26

Development stage: Preclinical
Lead developer: Gudui BioPharma
Modality: Small Molecules

Overview

GD-26 is a small molecule drug candidate being developed by Gudui BioPharma for the treatment of insomnia. Currently in the preclinical stage of development, GD-26 is characterized as a multi-target agent, meaning it is designed to interact with multiple biological pathways involved in the regulation of the sleep-wake cycle. While the specific molecular targets have not been publicly disclosed, this polypharmacological approach is often intended to enhance therapeutic efficacy and improve sleep maintenance or induction compared to single-target sedatives.

Beyond the preview

Go deeper on GD-26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GD-26.

Explore the full profile